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With rising antibacterial resistance, the need for new antibiotics is increasing. Antibiotics kill
the bacteria by interfering with a vital function of bacterial lifecycle. The most common
mechanism of antibiotics is to inhibit the enzymes involved in the bacterial cell wall synthesis.
The dapE-encoded N-succinyl-L,L-diaminopimelic acid desuccinylase (DapE) is a critical
enzyme found in the bacterial lysine biosynthetic pathway. Lysine is an essential amino acid
for humans, so since there is no similar pathway in humans inhibiting this enzyme would be
ideal. This enzyme is present in 98% of Gram negative and in all Gram-positive bacteria. Thus
inhibitors of DapE could serve as broad-spectrum antibiotics especially when targeting
multiple drug resistant ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Pseudomonas aeruginosa, and Enterobacter species) pathogens. Studies have
shown that when the gene encoding the DapE enzyme is deleted the bacteria cannot survive
even in a lysine supplemented media. DapE is a homodimeric metalloenzyme and the active






The Becker research lab has obtained five lead molecules through high-throughput screening
(HiTS), one being the tetrazole-based analog (Figure 1). Synthesis of the bioisosteric analogs
of the tetrazole hit and obtaining their inhibitory potencies using our ninhydrin-based assay
will be the focus of this project.
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Figure 1. Tetrazole-based lead 
molecule.
Synthesis of Pyrazole-based Analogs
Future Work
Figure 2:  (A) Open 
conformation of apo-HiDapE
enzyme, (B) Closed 
conformation of HiDapE
products-bound structure.
Figure 3. Interactions of (A) tetrazole original hit 
and (B) pyrazole analog with the DapE active site.
DapE is a homodimeric metalloenzyme 
and the active sites contain two zinc ions 
(Figure 2). DapE has two conformations: 
open and closed. The dynamic between 
the open to closed conformation is 
induced by the binding of the substrate. 
Docking images of tetrazole original lead 
molecule and the hit-derived pyrazole
analog show the interactions with different 
residues in the DapE active site which is 
useful to find the pharmacophore of our 
lead molecule (Figure 3). 
The rest of the analogs 
in the table above will 
be synthesize. The 
inhibitor molecules 
will be tested against 
DapE using our 
ninhydrin assay to 
study the in vitro 
inhibition of DapE. 
The final goal of this 




driven by SAR and 
computer simulations.
Due to the increase in antibacterial resistance, there is an urgent need for novel antibacterial drugs. The target enzyme for this project is the dapE-encoded bacterial enzyme N-succinyl-L,L-diaminopimelic acid desuccinylase (DapE). 
The lysine pathway that the DapE enzyme is a part of is absent in mammals, thus DapE inhibitors should selectively target bacteria and will be lethal to bacteria with no mechanism-based toxicity in humans. DapE is a key enzyme in 
the lysine biosynthetic pathway and products of which are precursors in bacterial cell wall synthesis. Thus, DapE enzyme is an ideal novel antibiotic target. The lead molecules identified by the Becker lab via a High-Throughput screen 























N-succinyl-L,L-diaminopimelic acid (L,L-SDAP) Succinate L,L-diaminopimelate
Scheme 2. Generalized reaction scheme for the thio-linked pyrazole-based inhibitor series. 
Figure 4. R groups 




































































Figure 5. Pyrazole analogs that are currently being synthesized. 
